logo
Fresno hospital system quietly cuts hundreds of nursing supervisor roles

Fresno hospital system quietly cuts hundreds of nursing supervisor roles

Yahoo05-06-2025

In the Spotlight is a Fresno Bee series that digs into the high-profile local issues that readers care most about. Story idea? Email tips@fresnobee.com.
Fresno's largest healthcare system discreetly slashed hundreds of nursing supervisor positions in recent weeks as part of a staffing shakeup.
Nearly 300 clinical nursing supervisors employed by Community Health System were informed that they had to decide whether to take a pay cut, apply for a leadership position or accept a severance package.
A March 4 letter obtained by The Bee confirms CHS notified Fresno city and county officials about plans to eliminate 285 positions due to the hospital system 'restructuring its operations.' The letter said the layoffs impacted 180 positions at Community Regional Medical Center, as well as 19 positions at Fresno Heart & Surgical Hospital and 86 positions at Clovis Community Medical Center.
The layoffs at CHS took effect May 3, weeks before news broke that the health system agreed to settle a federal probe and pay a $31.5 million fine, raising questions for some staff members.
Last month, CHS entered a massive settlement agreement announced last month by the U.S. Attorney's Office. The settlement addresses allegations that CHS was involved in a multi-year kickback scheme in which hospital executives provided expensive wine, liquor, cigars and meals to physicians in exchange for patient referrals.
CHS denies the settlement was the reason for the staffing changes.
'Community frequently evaluates our care model to assure that we have the right staffing mix to meet changing patient care needs,' Daniel Davis, R.N. division president of hospitals for CHS, said in a statement.
'This shift was driven solely by clinical best practice and patient care needs and was not designed to achieve cost savings,' Davis said.
Any company with 75 or more employees must file a WARN notice if it lays off 50 or more employees in a 30-day period, according to state law.
Hospital spokesperson Mary Lisa Russell said a WARN notice was sent out in early March, as required by law.
However, a spokesperson for the state's Employment Development Department said they had no record of a WARN notice from CHS.
Two nurse supervisors said the 285 impacted employees were forced to apply to new leadership positions, or take a demotion, with the majority taking big pay cuts.
'We were told that these changes had nothing to do with finances. That is incredibly hard to believe,' said one former nursing supervisor who spoke on condition of anonymity due to fear of professional retaliation.
The nursing supervisor said rumors started circulating in February about the elimination of clinical nursing supervisor roles.
She said affected staff met individually with human resources to explore their options — either applying for assistant nurse manager, charge nurse or clinical nurse ladder positions, or accept a severance package. CHS also offered two-year retention bonuses. Most positions offered lower pay than the eliminated supervisor role.
Another nursing supervisor who had worked at Community for more than a decade — who said she loved her job and had no discipline record — accepted a severance package after her position was eliminated. The supervisor said she thinks the restructuring was a cost-saving measure.
She said employees and patient care were sacrificed to pay for leadership's actions. Clinical supervising nurses who accepted other nursing positions have to be retrained on charting and other bedside nurse responsibilities, she said.
'I loved working here, I love my team,' she said.
Davis said CHS developed a new job description for assistant nurse manager, which is a model of clinical leadership and staffing followed by other local hospitals like Kaiser, Kaweah Health and Sutter Health.
'Based on those needs and industry best practice to support nursing at the bedside, we transitioned away from Clinical Nursing Supervisors and toward a combined Assistant Nurse Manager and Charge Nurse model,' Davis said.
Davis said that 247 of the 285 affected nurses transitioned to new roles.
'Only a small percentage chose to separate,' he said.
He also said in the coming months, 'nearly 95% of our workforce will see compensation increases as we continue to implement an organization-wide set of adjustments to align with California's new healthcare minimum wage.'
A new state law signed by Gov. Gavin Newsom in 2023 requires an increase in the minimum wage for workers at several eligible healthcare facilities.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vapes Clouds Contain Absolutely Horrifying Chemicals, Scientists Find
Vapes Clouds Contain Absolutely Horrifying Chemicals, Scientists Find

Yahoo

timea day ago

  • Yahoo

Vapes Clouds Contain Absolutely Horrifying Chemicals, Scientists Find

If you vape — and especially if it's because you think it's a less harmful alternative to smoking — then we have some really bad news. New research from the University of California, Davis, shows that some popular disposable vapes contain levels of toxic metals so appalling that they exceed traditional cigarettes. And we don't just mean a single cig — we're talking packs of them. The work, published as a study in the journal ACS Central Science, sounds the alarm on the vast amounts of unregulated if not illegal disposable vapes in the US that remain a favorite of teens. "When I first saw the lead concentrations, they were so high I thought our instrument was broken," study coauthor Mark Salazar, a researcher at UC Davis, said in a statement about the work. For their study, the researchers focused on vapes from three popular brands: ELF Bar, Esco Bar, and Flum Pebble. The tests involved activating the vapes and creating between 500 to 1,500 puffs for each one and analyzing the vape clouds. Afterwards, they disassembled the vapes to see where the contaminants were coming from. The findings were immediately alarming. Salazar and his colleagues discovered concentrations of toxic forms of metals like nickel, chromium, and antimony in most of the tested vapes. To quickly sum up what makes these metals bad: the type of nickel the researchers detected can cause lung and nasal cancer; chromium is also considered a carcinogen; and antimony can lead to heart and lung problems when inhaled as a dust and cause vomiting when swallowed. That brings us to lead. Two vapes from Esco Bar were absolutely reeking with it; on average, the devices from this brand emitted more lead in the first 200 puffs than smoking twenty packs of cigarettes. The contamination appears to be caused both by the components of actual vape and the nicotine juice they contain. "We found that these disposable devices have toxins already present in the e-liquid, or they're leaching quite extensively from their components into e-liquids and ultimately transferred to the smoke," Salazar said. Overall, two of the vapes emitted enough nickel and antimony levels to exceed cancer risk limits, the researchers said, while four vapes had nickel and lead emissions severe enough to be considered a risk for causing neurological damage and respiratory diseases. Bear in mind that this is what the researchers found by testing just three of some of the most well-known disposable vape brands. There are hundreds of other brands out there of even murkier origins, most imported from China. And while we're still only beginning to grapple with their health hazards, the findings line up with other research, including a study last year that found elevated uranium and lead levels in the urine of teens who regularly vaped. "Our study highlights the hidden risk of these new and popular disposable electronic cigarettes — with hazardous levels of neurotoxic lead and carcinogenic nickel and antimony — which stresses the need for urgency in enforcement," said senior author Brett Poulin, an assistant professor in the UC Davis Department of Environmental Toxicology, in the statement. More on vaping: We Talked to the Inventors of the "Tamagotchi" Vape That Dies If You Stop Puffing

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Miami Herald

time4 days ago

  • Miami Herald

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast DetailsThe dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13754335 The webcast link for the event can be found here: A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event. About ProtagonistProtagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to J&J Innovative Medicines ("JNJ"), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at Investor Relations ContactCorey Davis, Advisors+1 212 915 2577cdavis@ Media ContactVirginia Amann, Founder/CEOENTENTE Network of Companies+1 833 500 0061 ext 1virginiaamann@ SOURCE: Protagonist Therapeutics

Worthington Steel Announces Appointment of Mark Davis to Board of Directors and Audit Committee
Worthington Steel Announces Appointment of Mark Davis to Board of Directors and Audit Committee

Business Wire

time5 days ago

  • Business Wire

Worthington Steel Announces Appointment of Mark Davis to Board of Directors and Audit Committee

COLUMBUS, Ohio--(BUSINESS WIRE)--Worthington Steel, Inc. (NYSE: WS) announced today the appointment of Mark Davis to the Worthington Steel Board of Directors, effective immediately. Davis will serve as a member of the Audit Committee of the Board. 'We are pleased to welcome Mark Davis to our board of directors,' said John Blystone, executive chairman of Worthington Steel. 'Mark's extensive background in finance, mergers and acquisitions and corporate governance will be a tremendous asset as we continue to grow and create value for our stakeholders.' Davis is a private investor and co-chair of Lank Acquisition Corp., which invests in minority and majority positions in both public and private companies. He has more than 30 years of experience in investment banking and corporate finance, including senior leadership roles at JPMorgan Chase overseeing its Mergers and Acquisitions Group, General Industry Investment Banking and Investment Banking Coverage for all corporate clients. Earlier in his career, Davis held senior positions at Salomon Brothers and began his investment banking career at Kidder, Peabody & Co. in mergers and acquisitions and corporate finance. He has served on the boards of Worthington Enterprises, Scott Paper Co., Valassis Industries Inc. and Manhattanville College, where he chaired the finance committee. Davis earned a Master of Business Administration from the Tuck School of Business and a bachelor's degree from Dartmouth College. About Worthington Steel Worthington Steel (NYSE:WS) is a metals processor that partners with customers to deliver highly technical and customized solutions. Worthington Steel's expertise in carbon flat-roll steel processing, electrical steel laminations and tailor welded solutions is driving steel toward a more sustainable future. As one of the most trusted metals processors in North America, Worthington Steel and its approximately 6,000 employees harness the power of steel to advance our customers' visions through value-added processing capabilities including galvanizing, pickling, configured blanking, specialty cold reduction, lightweighting and electrical lamination. Headquartered in Columbus, Ohio, Worthington Steel operates 37 facilities in seven states and 10 countries. Following a people-first Philosophy, commitment to sustainability and proven business system, Worthington Steel's purpose is to generate positive returns by providing trusted and innovative solutions for customers, creating opportunities for employees and strengthening its communities. Safe Harbor Statement Worthington Steel wishes to take advantage of the Safe Harbor provisions included in the Private Securities Litigation Reform Act of 1995 (the 'Act"). Statements by Worthington Steel which are not historical information constitute "forward-looking statements" within the meaning of the Act. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected. Factors that could cause actual results to differ materially include risks, uncertainties and impacts described from time to time in Worthington Steel's filings with the Securities and Exchange Commission.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store